Research Topic · Peer-Reviewed

Rivaroxaban

Rivaroxaban is an oral anticoagulant drug used to prevent blood clot formation. It belongs to a class of medications called factor Xa inhibitors and works by blocking certain proteins, in particular factor Xa, that are involved in the clotting process of the body. This helps reduce the risk of deep vein thrombosis a…

Curated from this journal's research 📚 1 peer-reviewed article cited 🗓 Reviewed June 2026

Overview

Rivaroxaban is an oral anticoagulant drug used to prevent blood clot formation. It belongs to a class of medications called factor Xa inhibitors and works by blocking certain proteins, in particular factor Xa, that are involved in the clotting process of the body. This helps reduce the risk of deep vein thrombosis and other serious and life-threatening blood clots. Rivaroxaban is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). Additionally, it is used to treat or prevent deep vein thrombosis and pulmonary embolism. Rivaroxaban is also used in certain conditions to reduce the risk of major cardiovascular events, such as death and heart attack, in adults with coronary artery disease or peripheral arterial disease.

Research published in this journal

1 peer-reviewed article, ranked by relevance. Each links to its DOI.

Editorial oversight

Curated from peer-reviewed research published in Thrombosis and treatments.

Journal editorial board
Ioanna Koniari · Greece

This page summarises published research for orientation; it is not medical or professional advice.